Lyell Immunopharma, Inc.
LYELHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeLyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company carries a $230.1M market cap, placing it firmly in the micro-cap category. The company's lead product candidate include rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, which is in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting, as well as a second pivotal trial, PiNACLE-H2H, which is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma; and LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorec.
Market Cap
$230.1M
Beta
-0.03
P/E (TTM)
—
P/E (Fwd)
-1.49
EPS (TTM)
$-12.86
EPS (Fwd)
$-6.32
ROE
-93.3%
ROA
-34.2%
Cash
$204.1M
Total Debt
$46.6M
Free CF
-$72.8M
52W Change
-45.5%
Annual Financials
Cash vs Debt
Where LYEL stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, LYEL finished 42.71% below its 150-day moving average ($15.36) and 49.86% below its 200-day moving average ($17.55). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is LYEL overbought or oversold?
At the October 20, 2026 close, LYEL's RSI(14) was 40.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $204.1M in cash comfortably exceeding the $46.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$72.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -93.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $84.7M (2022) to $36K (2025), a 100% decline worth watching.
With a beta below 0.7, Lyell Immunopharma, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing LYEL.